Heterogeneity and therapeutic implications of cancer-associated fibroblasts in lung cancer: Recent advances and future perspectives

Chin Med J Pulm Crit Care Med. 2024 Oct 24;2(4):240-249. doi: 10.1016/j.pccm.2024.08.009. eCollection 2024 Dec.

Abstract

Lung cancer is a leading cause of cancer-related mortality. The tumor microenvironment is a complex and heterogeneous cellular environment surrounding tumor cells, including cancer-associated fibroblasts (CAFs), blood vessels, immune cells, the extracellular matrix, and various cytokines secreted by cells. CAFs are highly heterogeneous and play crucial roles in lung cancer. This review highlights recent advances in the understanding of CAFs in lung cancer, focusing on their heterogeneity and functions in tumorigenesis, progression, angiogenesis, invasion, metastasis, therapy resistance, tumor immune suppression, and targeted therapy responses. Additionally, we explore the underlying mechanisms and the potential of CAFs as a target in the development of innovative therapies for lung cancer.

Keywords: Biomarker; Cancer-associated fibroblasts; Lung cancer; Therapeutic resistance; Tumor microenvironment.

Publication types

  • Review